Last deal

$60.35M
Local Amount - CHF 60M

Amount

Series B

Stage

10.01.2016

Date

2

all rounds

$118.48M

Total amount

date founded

Financing round

General

About Company
Cardiorentis is a biopharmaceutical company focused on developing novel therapies for heart failure and related cardiovascular diseases.

Industry

Sector :

Subsector :

founded date

01.01.2010

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

The company specializes in the development of ularitide, an intravenous infusion treatment for acute heart failure. With a strong emphasis on scientific advancement and practical know-how, Cardiorentis is committed to enhancing the lives of patients through evidence-based drug treatments. The company works closely with academic researchers, universities, and practicing clinicians to drive important research forward and shape the future of patient care.
Contacts
Similar Companies
999
Quantum Genomics

Quantum Genomics

Quantum Genomics develops therapies for unmet medical needs in cardiovascular diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Paris, France
Cardurion Pharmaceuticals

Cardurion Pharmaceuticals

Cardurion is a biotechnology company that develops therapeutics for cardiovascular diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Life Science

Location

Boston, MA, USA

total rounds

6

total raised

$603.15M
MyoKardia

MyoKardia

MyoKardia develops targeted therapies for rare cardiovascular diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Brisbane, CA, USA

total rounds

5

total raised

$98M
Nuvelo

Nuvelo

Nuvelo, Inc. is a publicly traded company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

San Carlos, CA, USA

Financials

Funding Rounds
2
2

Number of Funding Rounds

$118.48M

Money Raised

Their latest funding was raised on 10.01.2016. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
10.01.2016
$60.35M
Local Amount - CHF 60M
18.09.2014
1
$58.13M
Local Amount - EUR 45M
HealthCare Royalty Partners

HealthCare Royalty Partners

HealthCare Royalty Partners is a global healthcare investment firm that invests in commercial stage healthcare product assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Stamford, CT, USA

total rounds

1

total raised

$680M

count Of Investments

26

count Of Exists

4
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
HealthCare Royalty Partners

HealthCare Royalty Partners

HealthCare Royalty Partners is a global healthcare investment firm that invests in commercial stage healthcare product assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Stamford, CT, USA

total rounds

1

total raised

$680M

count Of Investments

26

count Of Exists

4

People

Founders
1
Johannes Holzmeister
Johannes Holzmeister

Johannes Holzmeister

Johannes Holzmeister is the Chairman and Chief Executive Officer at DiNAQOR. He is an internationally recognized cardiologist and has nearly two decades of clinical research experience. Prior to co-founding Cardiorentis in 2010, he worked at the University Hospital of Zürich where he led the interventional device group for heart failure patients. Dr. Holzmeister’s research has been published in leading medical journals including The New England Journal of Medicine and The Lancet. He is a board-certified cardiologist and received his M.D. from Humboldt University of Berlin.

current job

DiNAQOR
DiNAQOR

organization founded

2

Johannes Holzmeister

Employee Profiles
2
Johannes Holzmeister

Johannes Holzmeister

Chairman and Chief Executive Officer

Activity

Recent News
0